Xencor, Inc. (XNCR) News
Filter XNCR News Items
XNCR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
XNCR News Highlights
- XNCR's 30 day story count now stands at 12.
- Over the past 22 days, the trend for XNCR's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- DRUG, BEAT and BIO are the most mentioned tickers in articles about XNCR.
Latest XNCR News From Around the Web
Below are the latest news stories about Xencor Inc that investors may wish to consider to help them evaluate XNCR as an investment opportunity.
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q4 2021 Results - Earnings Call TranscriptXencor, Inc. (XNCR) Q4 2021 Earnings Conference Call February 22, 2022, 17:00 ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & IR Bassil Dahiyat - Co-Founder, CEO, President & Director Allen Yang - SVP & Chief Medical Officer John Kuch - SVP & CFO John Desjarlais... |
Xencor GAAP EPS of $1.21 beats by $1.11, revenue of $154.02M beats by $77.73MXencor press release (XNCR): Q4 GAAP EPS of $1.21 beats by $1.11.Revenue of $154.02M (+268.0% Y/Y) beats by $77.73M.The company expects to have cash to fund research and… |
Xencor Reports Fourth Quarter and Full Year 2021 Financial ResultsMONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights. “In 2021, we made significant decisions to advance our portfolio of internal XmAb® drug candidates — the initiation of Phase 2 trials |
Xencor (XNCR) Q4 Earnings and Revenues Beat EstimatesXencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Shareholders in Xencor (NASDAQ:XNCR) have lost 35%, as stock drops 4.0% this past weekThe simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners... |
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022MONROVIA, Calif., February 16, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that it will provide a corporate update and report financial results for the fourth quarter and full year 2021 after the market closes on Wednesday, February 23, 2022. |
Leerink Partners Thinks Xencor’s Stock is Going to RecoverIn a report released yesterday, Jonathan Chang from Leerink Partners maintained a Buy rating on Xencor (XNCR – Research Report), with a price target of $49.00. The company's shares closed last Tuesday at $34.14, close to its 52-week low of $30.12. According to TipRanks.com, Chang is ranked 0 out of 5 stars with an average return of -12.6% and a 21.3% success rate. Chang covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Harpoon Therapeutics, and Bicycle Therapeutics. Xencor has an analyst consensus of Strong Buy, with a price target consensus of $57.67, which is a 73.0% upside from current levels. |
Xencor (XNCR) to Report Q4 Results: Wall Street Expects Earnings GrowthXencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsightLas Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythemat... |
Xencor to Present at Upcoming Investor ConferencesMONROVIA, Calif., February 02, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming virtual investor conferences: |